Search

Your search keyword '"Cannella, L"' showing total 244 results
Start Over Author "Cannella, L"
244 results on '"Cannella, L"'

3. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial

Author

Baron, F., Efficace, F., Cannella, L., Stevens-Kroef, M.J.P.L., Amadori, S., Witte, T.J. de, Lübbert, M., Venditti, A., Suciu, S., Baron, F., Efficace, F., Cannella, L., Stevens-Kroef, M.J.P.L., Amadori, S., Witte, T.J. de, Lübbert, M., Venditti, A., and Suciu, S.

Abstract

Contains fulltext : 304916.pdf (Publisher’s version ) (Closed access), We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow (ABMT) in acute myeloid leukemia (AML) patients in first remission (CR). We observed that among patients alive and still in CR 5 years after planned auto-HSCT, approximately 10% of the patients died in the following 10 years. This stresses the need for long-term close surveillance of AML patients after auto-HSCT. Further, long-term follow-up of the trial confirms that APBSCT was comparable to ABMT in term of disease-free-survival and overall survival.

Published
2024

12. 1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial

Author

Clemente, O., Starita, N., Bracigliano, A., Cives, M., Tatangelo, F., Barretta, M.L., Badalamenti, G., Lastoria, S., Picozzi, F., Di Mauro, A., von Arx, C., Cannella, L., and Tafuto, S.

Published
2023
Full Text
View/download PDF

16. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study

Author

Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C.J., Fazi, P., Vignetti, M., Marie, J.P., Chiusolo, P., Velden, W.J. van der, La Sala, E., Vitolo, U., Thomas, X., Lefrere, F., Raimondo, F. Di, Bourhis, J.H., Specchia, G., Guimaraes, J.E., Allione, B., Vrhovac, R., Ferrara, F., Stevens-Kroef, M.J., Meert, L., Witte, T.J. de, Willemze, R., Amadori, S., Suciu, S., Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C.J., Fazi, P., Vignetti, M., Marie, J.P., Chiusolo, P., Velden, W.J. van der, La Sala, E., Vitolo, U., Thomas, X., Lefrere, F., Raimondo, F. Di, Bourhis, J.H., Specchia, G., Guimaraes, J.E., Allione, B., Vrhovac, R., Ferrara, F., Stevens-Kroef, M.J., Meert, L., Witte, T.J. de, Willemze, R., Amadori, S., and Suciu, S.

Abstract

Item does not contain fulltext, We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m(2) ), mitoxantrone (MXR, 12 mg/m(2) ), or idarubicin (IDA, 10 mg/m(2) ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.

Published
2020

17. Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Author

Baron, F., Efficace, F., Cannella, L., Willemze, R., Vignetti, M., Muus, P., Marie, J.P., Ferrero, D., Fazi, P., La Sala, E., Bourhis, J.H., Fabbiano, F., Bosi, A., Sborgia, M., Martinelli, G., Wittnebel, S., Trisolini, S., Petti, M.C., Halkes, C.J., Velden, W.J.F.M. van der, Witte, T.J. de, Amadori, S., Zittoun, R.A., Suciu, S., Baron, F., Efficace, F., Cannella, L., Willemze, R., Vignetti, M., Muus, P., Marie, J.P., Ferrero, D., Fazi, P., La Sala, E., Bourhis, J.H., Fabbiano, F., Bosi, A., Sborgia, M., Martinelli, G., Wittnebel, S., Trisolini, S., Petti, M.C., Halkes, C.J., Velden, W.J.F.M. van der, Witte, T.J. de, Amadori, S., Zittoun, R.A., and Suciu, S.

Abstract

Contains fulltext : 218286.pdf (publisher's version ) (Open Access)

Published
2020

24. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib

Author

Cannella L, D Germano, V Tinessa, Barletta E, and B Daniele

Subjects
Niacinamide, Oncology, Sorafenib, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.medical_treatment, Antineoplastic Agents, Pharmacology, Targeted therapy, chemistry.chemical_compound, Pharmacotherapy, Internal medicine, medicine, Humans, Pharmacology (medical), Molecular Targeted Therapy, Tivantinib, neoplasms, Aged, Everolimus, business.industry, Phenylurea Compounds, Liver Neoplasms, medicine.disease, digestive system diseases, Clinical trial, Linifanib, Clinical Trials, Phase III as Topic, chemistry, Hepatocellular carcinoma, Geriatrics and Gerontology, business, medicine.drug
Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Worldwide progressive population aging demands consensus development for decision making when treating elderly patients. Age itself might not be a critical determinant for the selection of a therapeutic option. In the past few years, the mechanisms of hepato-carcinogenesis have been elucidated, and the involvement of a number of pathways, including angiogenesis, aberrant signal transduction, and dysregulated cell cycle control, have been demonstrated, leading to evaluation of the activity and toxicity of some of the new molecularly targeted agents. Sorafenib was demonstrated to significantly increase the survival of patients with advanced HCC in two prospective, randomized, placebo-controlled trials. Subsequently, a number of retrospective or prospective studies have indicated that the effectiveness of sorafenib therapy in the treatment of HCC is similar in elderly and non-elderly patients. The aim of this review is to describe the impact of age on the effects of sorafenib-targeted therapy in patients with HCC, and the next treatment options with new targeted agents (everolimus, tivantinib, linifanib, etc.).

Published
2013
Full Text
View/download PDF

25. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Author

Daniele, G, Lorusso, D, Scambia, G, Cecere, S, Nicoletto, M, Breda, E, Colombo, N, Artioli, G, Cannella, L, Lo Re, G, Raspagliesi, F, Maltese, G, Salutari, V, Ferrandina, G, Greggi, S, Baldoni, A, Bergamini, A, Piccirillo, M, Tognon, G, Floriani, I, Signoriello, S, Perrone, F, Pignata, S, COLOMBO, NICOLETTA, Pignata, S., Daniele, G, Lorusso, D, Scambia, G, Cecere, S, Nicoletto, M, Breda, E, Colombo, N, Artioli, G, Cannella, L, Lo Re, G, Raspagliesi, F, Maltese, G, Salutari, V, Ferrandina, G, Greggi, S, Baldoni, A, Bergamini, A, Piccirillo, M, Tognon, G, Floriani, I, Signoriello, S, Perrone, F, Pignata, S, COLOMBO, NICOLETTA, and Pignata, S.

Abstract

Background Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. Methods 400 chemonaïve epithelial ovarian cancer patients, age ≥ 18, ECOG PS 0–2 were eligible to receive C (AUC 5 d1, q21) plus P (175 mg/m2 d1, q21) and B (15 mg/kg d1 q21) for 6 cycles followed by B maintenance until cycle 22nd. Results 79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤ 1 cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. Conclusions In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.

Published
2017

26. Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study

Author

CARLOMAGNO, Chiara, BUCCI, LUIGI, D'ARMIENTO, FRANCESCO PAOLO, PACELLI, ROBERTO, DE STEFANO, ALFONSO, D'ARMIENTO, MARIA, DE PLACIDO, SABINO, Farella A, Pesce G, Pepe S, Cannella L, Solla R, Carlomagno, Chiara, Farella, A, Bucci, Luigi, D'Armiento, FRANCESCO PAOLO, Pesce, G, Pepe, S, Cannella, L, Pacelli, Roberto, DE STEFANO, Alfonso, Solla, R, D'Armiento, Maria, and DE PLACIDO, Sabino

Subjects
rectal, neoadjuvant, chemoradiotherapy
Abstract

Background. Pre-operative chemoradiation is now standard treatment for stage II-III rectal cancer. Capecitabine (CAP) and oxaliplatin (OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms. Patients and Methods. Two cycles of CAP 825 mg/m2 bid (days 1-14) and OX 50 mg/m2 (days 1 & 8) every 3 weeks were given concomitantly with pelvic conformal RT (45 Gy). Patients with a ≥ T3 and/or node-positive rectal tumour were eligible. The pathologic tumour response was defined according to the Tumour Regression Grade (TRG) scale. Results. Forty-six patients were enrolled. Gastrointestinal adverse events were mostly G1-G2; only 2 patients experienced G3 vomiting and diarrhoea; 6 patients had G1 peripheral neuropathy. Haematological toxicity was rare. G2 proctitis and anal pain occurred in 2 patients. Pathological complete response (TRG1) was observed in 9 patients (20.9%; 95% CI 8.7-33.1%); TRG2 in 19 patients (44.2%); TRG3 in 12 patients (27.9%); TRG4 in 3 patients (7%). Overall, 9 patients recurred: 5 with distant metastases, 1 with local recurrence, and 3 with both local recurrence and distant metastases. Conclusions. CAP-OX-RT as pre-operative treatment for rectal cancer induces a remarkable rate of complete or near-complete pathological responses, and is well tolerated.

Published
2009

27. Skin lesions: unusual presentation of gastric cancer

Author

Alfieri S, Colantuoni M, De Stefano A, CAnnella L, Cella CA, CARLOMAGNO, Chiara, DE PLACIDO, SABINO, Alfieri, S, Carlomagno, Chiara, Colantuoni, M, De Stefano, A, Cannella, L, Cella, Ca, and DE PLACIDO, Sabino

Subjects
skin, gastric cancer, metastasis
Published
2009

28. Predictive factors of response to neoadjuvant chemoradiotherapy in rectal cancer patients

Author

CARLOMAGNO, Chiara, D'ARMIENTO, FRANCESCO PAOLO, D'ARMIENTO, MARIA, DE PLACIDO, SABINO, Crispo A, Della Vittoria Scarpati G, Marra M, Cannella L, De Stefano A, Colantuoni M, Alfieri S, Pepe S., Carlomagno, Chiara, D'Armiento, FRANCESCO PAOLO, Crispo, A, Della Vittoria Scarpati, G, D'Armiento, Maria, Marra, M, Cannella, L, De Stefano, A, Colantuoni, M, Alfieri, S, DE PLACIDO, Sabino, and Pepe, S.

Subjects
predictive factor, rectal cancer, chemoradiotherapy
Published
2008

29. Naoadjuvant chemoradiation therapy with capecitabine (CAP) and oxaliplatin (OX) in rectal cancer: final results of a phase II study

Author

CARLOMAGNO, Chiara, D'ARMIENTO, FRANCESCO PAOLO, Farella A, Cannella L, De Stefano A, Colantuoni M, Alfieri S, Marra M, Totaro G, Pepe S., Carlomagno, Chiara, D'Armiento, FRANCESCO PAOLO, Farella, A, Cannella, L, De Stefano, A, Colantuoni, M, Alfieri, S, Marra, M, Totaro, G, and Pepe, S.

Subjects
capecitabine, oxaliplatin, rectal neoadjuvant, chemoradiotherapy
Published
2008

30. Neoadjuvant chemoradiation therapy and pedictive factors of response to Capecitabine (CAP) and Oxaliplatin (OX) in rectal cancer patients: a phase II study

Author

De Stefano A, Cannella L, Crispo A, Pepe S., CARLOMAGNO, Chiara, D'ARMIENTO, FRANCESCO PAOLO, FARELLA, ANTONIO, DE PLACIDO, SABINO, De Stefano, A, Cannella, L, Carlomagno, Chiara, D'Armiento, FRANCESCO PAOLO, Farella, Antonio, Crispo, A, DE PLACIDO, Sabino, and Pepe, S.

Subjects
predictive factors, rectal, chemoradiotherapy
Published
2008

43. Bevacizumab-induced hypertension is a predictive marker of response and progression free survival in patients treated for metastatic colorectal cancer

Author

DE STEFANO, A., Carlomagno, C., Cannella, L., Crispo, A., Pepe, Stefano, Alfieri, S., Colantuoni, M., Cella, C., Raimondo, L., DE PLACIDO, S., DE STEFANO, Alfonso, Carlomagno, Chiara, L., Cannella, A., Crispo, S., Pepe, S., Alfieri, M., Colantuoni, Ac, Cella, L., Raimondo, and DE PLACIDO, Sabino

Subjects
predictive factor, colorectal, hypertension, bevacizumab
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results